Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan

Executive Summary

Bringing the hammer down on biopharma, HHS Secretary Azar says department could use demonstration projects to switch drugs from Medicare Part B to Part D.

Related Content

Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means
Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown
Oncologists Move Against Medicare Part B Drug Payment, Pricing ‘Attacks’
US Drug Pricing Reform: No More Medicare 'Gravy Train,' Azar Tells Pharma
REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
Part B Drug Competitive Bidding Program Revival: Vendor Request Coming Soon
Gottlieb's 2018 Generic Drug Approval Goal May Be In Doubt
Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts
How Drug Promotion Might Change Under Trump's Rx Pricing Plan





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts